Peptide Initiative

Peptides · Peptide comparison

Orforglipron vs Semaglutide

First oral non-peptide GLP-1 receptor agonist for diabetes and obesity

The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeOrforglipron0.8–17.2 mgSemaglutide0.5–1 mg
FrequencyOrforglipronOnce dailySemaglutideOnce weekly
AdministrationOrforglipronoralSemaglutideSubcutaneous injection
Cycle lengthOrforglipronOngoing/indefiniteSemaglutideOngoing/indefinite
Onset speedOrforglipronModerate (1-2 weeks)SemaglutideModerate (1-2 weeks)
Evidence levelOrforglipronStrong human trials (Phase 3 or FDA approved)SemaglutideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Weight Management

Orforglipron9%
SemaglutideNo recorded rating

Blood Sugar Control

Orforglipron9%
SemaglutideNo recorded rating

Cardiovascular Health

Orforglipron7%
SemaglutideNo recorded rating

Weight Loss

OrforglipronNo recorded rating
Semaglutide98%

Appetite Control

OrforglipronNo recorded rating
Semaglutide95%

Heart Protection

OrforglipronNo recorded rating
Semaglutide92%

Technical data

Compound specifications

Orforglipron

Molecular formula
C48H48F2N10O5
Molecular weight
883.0 Da
Half-life
About 29–49 hours (elimination half-life after an oral dose)
Bioavailability
77% absolute oral bioavailability (0.8 mg dose); no clinically relevant food effect
CAS number
2212020-52-3

Semaglutide

Molecular formula
C187H291N45O59
Molecular weight
4113.58 g/mol
Half-life
Approximately 7 days (168 hours)
Bioavailability
89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
CAS number
910463-68-2

Protocols

Dosing compared

Orforglipron

Oral

  • At least 30 days0.8 mg once dailyOnce daily, with or without food · At least 30 daysLabel starting dose. After at least 30 days, increase to 2.5 mg once daily, then after at least 30 more days to 5.5 mg once daily; gradual escalation reduces gastrointestinal reactions [7]. Tablets are swallowed whole, one per day [7].
  • Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mg5.5 mg once dailyOnce daily, with or without food · Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mgFirst maintenance-level dose on the label's escalation [7]. In the phase 3 trial without diabetes, 5.5 mg produced 7.4% average weight loss at 72 weeks against 2.1% on placebo [7].
  • Ongoing; each step after at least 30 days on the previous dose9–17.2 mg once dailyOnce daily, with or without food · Ongoing; each step after at least 30 days on the previous doseOptional further steps of 9 mg, 14.5 mg and 17.2 mg based on response and tolerability; 17.2 mg is the maximum, and 9 mg is the maximum alongside a strong CYP3A4 inhibitor [7]. 17.2 mg produced 11.1% average weight loss at 72 weeks against 2.1% on placebo [7].

Semaglutide

Subcutaneous

  • 4 weeks0.25 mgOnce weekly · 4 weeksThis is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
  • At least 4 weeks at each step0.5-1 mgOnce weekly · At least 4 weeks at each stepAfter the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
  • Ongoing/maintenance2-2.4 mgOnce weekly · Ongoing/maintenanceThe highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.

Oral

  • 30 days3 mgOnce daily · 30 daysThe pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills [6].
  • 30+ days7 mgOnce daily · 30+ daysAfter the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar [6].
  • Ongoing/maintenance14 mgOnce daily · Ongoing/maintenanceThe highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg [6].

Applications

Best suited for

Orforglipron

Oral GLP-1 receptor agonism without injection burden
Orforglipron is particularly well-suited for individuals focused on oral glp-1 receptor agonism without injection burden. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Weight management in obesity with or without type 2 diabetes
Orforglipron is particularly well-suited for individuals focused on weight management in obesity with or without type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Glycemic control in type 2 diabetes as add-on to metformin
Orforglipron is particularly well-suited for individuals focused on glycemic control in type 2 diabetes as add-on to metformin. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Cardiovascular risk reduction through weight loss and metabolic improvements
Orforglipron is particularly well-suited for individuals focused on cardiovascular risk reduction through weight loss and metabolic improvements. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Semaglutide

People with Obesity Seeking Significant Weight Loss
If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. [7] Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds [1].
Those Who've Struggled with Diet and Exercise Alone
Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less [3][7][13].
People with Type 2 Diabetes Needing Better Control
Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. [3][5] It can often allow people to reduce or eliminate other diabetes medications [21].
Individuals at High Cardiovascular Risk
The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes [2].

Safety profile

Side effects

Orforglipron

Common

  • Nausea
  • Constipation
  • Diarrhea
  • Vomiting

Uncommon

  • Heart Rate Increase

Serious

  • Pancreatitis Risk

Semaglutide

Common

  • Nausea
  • Constipation or Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Loss (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research status

Safety & evidence

Orforglipron

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use — as FOUNDAYO (orforglipron) tablets, on 1 April 2026, for long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition. Not approved for type 2 diabetes.
Safety overview
Orforglipron is FDA approved as FOUNDAYO (April 2026) for long-term weight management. [7][8] Its label carries a boxed warning on thyroid C-cell tumours seen with GLP-1 receptor agonists in rodents — orforglipron itself is not active in rats or mice and caused no rodent tumours — and contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2. [7] In the two phase 3 weight trials, gastrointestinal reactions affected 60–69% of patients against 37% on placebo, mostly mild or moderate and most frequent during dose escalation; 8% stopped treatment for adverse reactions against 3% on placebo. [7] Labelled warnings also cover acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from dehydration, hypoglycaemia with insulin or a sulfonylurea, hypersensitivity, diabetic retinopathy complications, gallbladder disease and pulmonary aspiration under anaesthesia. [7]

Contraindications

  • Personal or family history of medullary thyroid carcinoma (boxed-warning contraindication) [7]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [7]
  • Known hypersensitivity to orforglipron or excipients [7]
  • History of pancreatitis (use with caution)

Semaglutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. [1][2][8][9][10] The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. [1][7] The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss [2].

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) [7]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [7]
  • History of serious allergic reaction to semaglutide [7]

Decision guide

Which is right for you?

Orforglipron

Choose Orforglipron if…

  • Oral GLP-1 receptor agonism without injection burden
  • Weight management in obesity with or without type 2 diabetes
  • Glycemic control in type 2 diabetes as add-on to metformin
  • Cardiovascular risk reduction through weight loss and metabolic improvements

Semaglutide

Choose Semaglutide if…

  • Significant weight loss
  • Long-term weight management
  • Cardiovascular risk reduction
  • Blood sugar control